Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program First global pivotal Phase III in c-Met- driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near futureCo-Development Agreement • August 1st, 2016 • Hutchison China MediTech LTD • Pharmaceutical preparations
London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 global licensing, co-development, and commercialisation agreement (the “2011 Agreement”) regarding savolitinib. Based on data from multiple Phase I/II studies, savolitinib has shown early clinical benefit as a highly selective c-Met inhibitor in a number of cancers.
